Greenwich LifeSciences presents FLAMINGO-01 immune response data

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. WDC
2. DECK
3. RNG
4. BYD
5. WCN
6. SPOT
7. FIX
8. BE
9. BMY
10. NDAQ

Go back to Greenwich LifeSciences presents FLAMINGO-01 immune response data

Greenwich LifeSciences Presents FLAMINGO-01 Phase III Trial Open Label Data Published at ASCO Meeting 2026

June 1, 2026 8:15 AM EDT

STAFFORD, Texas, June 01, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an immunotherapy to prevent breast cancer recurrences, today presents the published abstract and poster from the ASCO Annual Meeting 2026.

The abstract is shown below and the poster being presented today can be seen and downloaded at the bottom of the Phase III clinical trial tab on the Company's website... More